Woodline Partners LP Rain Therapeutics Inc. Transaction History

Woodline Partners LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.77 - $12.47 $1.05 Million - $1.68 Million	-134,928 Reduced 52.99%	119,700 $1.05 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $8.48 $744,802 - $1.14 Million	134,928 Added 112.72%	254,628 $2.04 Million
Q2 2021 Aug 16, 2021	BUY	$15.08 - $20.3 $1.81 Million - $2.43 Million	119,700 New	119,700 $1.86 Million

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.